ResultsIQ

ResultsIQ › Latest results › Aster DM Quality Care Limited

Aster DM Quality Care Limited Q4 FY25 earnings call summary

NSE: ASTERDM · BSE: 540975

Earnings call of 21 May 2025, summarised by AI from the filing.

Aster DM Healthcare reports FY25 revenue of ₹4,138 cr, up 12%, and expects mid-teens growth in FY26 with QCIL merger on track for Q4 FY26.

Key takeaways

  1. FY25 revenue ₹4,138 cr, up 12% year-on-year, driven by 7% inpatient volume growth and 12% ARPOB increase.
  2. Kerala risk Kerala cluster Q4 occupancy impacted by Ramadan and lower MVT; recovery expected in next few quarters.

Original filing on BSE

Aster DM Quality Care Limited Q1 FY27 results

As filed: Revenue ₹1,311 cr (+22% year on year), EBITDA ₹264 cr (+28% year on year), PAT ₹29.3 cr (+38% year on year), EBITDA margin 20.2% (+96 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹1,182 cr (+18% year on year), EBITDA ₹233 cr (+21% year on year), PAT ₹154 cr (+79% year on year), EBITDA margin 19.7% (+47 bps). Score 48 of 100, In line with trend. Revenue, EBITDA and profit growth were above the company's own trend. EBITDA margin rose 47 bps year on year. Tax rate 6%. Consolidated profit +79% but standalone -55%. Share price after the results: +3.9% in 29 days (Nifty 500: −0.1%).
  • Q3 FY26: Revenue ₹1,186 cr (+13% year on year), EBITDA ₹211 cr (+12% year on year), PAT ₹58.7 cr (+9% year on year), EBITDA margin 17.8% (−18 bps). Score 36 of 100, Below trend. Revenue growth was above the company's own trend; EBITDA growth was in line with it; profit before exceptional items growth was below it. EBITDA margin fell 18 bps year on year. Other income 25% of PBT. Tax rate 40%. Profit fell 23% from last quarter. Share price after the results: +14.8% in 28 days (Nifty 500: +0.4%).
  • Q2 FY26: Revenue ₹1,197 cr (+10% year on year), EBITDA ₹250 cr (+14% year on year), PAT ₹121 cr (+14% year on year), EBITDA margin 20.9% (+72 bps). Score 51 of 100, In line with trend. Revenue and profit growth were in line with the company's own trend; EBITDA growth was above it. EBITDA margin rose 72 bps year on year. Share price after the results: −7.6% in 29 days (Nifty 500: +1.4%).
  • Q1 FY26: Revenue ₹1,078 cr (+8% year on year), EBITDA ₹207 cr (+27% year on year), PAT ₹94.0 cr (−98% year on year), EBITDA margin 19.2% (+293 bps). Score 50 of 100, In line with trend. Revenue growth was in line with the company's own trend; EBITDA growth was above it; profit growth was below it. EBITDA margin rose 293 bps year on year. Share price after the results: +1.4% in 30 days (Nifty 500: −2.5%).
  • Q4 FY25: Revenue ₹1,000 cr (+3% year on year), EBITDA ₹192 cr (+21% year on year), PAT ₹86.0 cr (+69% year on year), EBITDA margin 19.2% (+288 bps). Score 43 of 100, In line with trend. Revenue growth was in line with the company's own trend; EBITDA and profit before exceptional items growth were above it. EBITDA margin rose 288 bps year on year. Other income 31% of PBT. Tax rate 5%. Revenue fell 5% from last quarter. Share price after the results: +1.4% in 30 days (Nifty 500: +1.4%).
  • Q3 FY25: Revenue ₹1,050 cr (−72% year on year), EBITDA ₹189 cr (−67% year on year), PAT ₹64.0 cr (−47% year on year), EBITDA margin 18.0% (+277 bps). Score 11 of 100, Below trend. Revenue and EBITDA growth were well below the company's own trend; profit before exceptional items growth was below it. EBITDA margin rose 277 bps year on year. Other income 31% of PBT. Tax rate 36%. Revenue fell 3% from last quarter.
  • Q2 FY25: Revenue ₹1,086 cr (−67% year on year), EBITDA ₹219 cr (−42% year on year), PAT ₹106 cr, EBITDA margin 20.2% (+880 bps). Score 21 of 100, Below trend. EBITDA margin rose 880 bps year on year. Not enough history for a trend yet: scored on growth alone. Profit fell 98% from last quarter.

Past price moves after results do not indicate future moves. Not a recommendation.

Aster DM Quality Care Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.